Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1150690 | 1.00 | CA12 (0.40) | CA12CA1CA2CA9FKBP1A | |
| SCHEMBL1150296 | 0.82 | CA12 (0.44) | CA12CA1CA2CA9FKBP1A | |
| SCHEMBL29022309 | 0.82 | CA12 (0.44) | CA12CA1CA2CA9FKBP1A | |
| SCHEMBL28897030 | 0.80 | CA12 (0.40) | CA12CA1CA2CA9FKBP1A | |
| SCHEMBL29122407 | 0.78 | CA12 (0.46) | CA12CA1CA2CA9FKBP1A | |
| SCHEMBL22091994 | 0.78 | CA12 (0.46) | CA12CA1CA2CA9FKBP1A | |
| SCHEMBL5742303 | 0.78 | CA12 (0.46) | CA12CA1CA2CA9FKBP1A | |
| SCHEMBL12857997 | 0.78 | SMN1; SMN2 (0.44) | CA12CA1CA2CA9LMNA | |
| SCHEMBL29123338 | 0.75 | CA12 (0.41) | CA12CA1CA2CA9FKBP1A | |
| SCHEMBL29123337 | 0.75 | CA12 (0.41) | CA12CA1CA2CA9FKBP1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034449-A1 | N-SUBSTITUTED HYDROXYPYRIMIDINONE CARBOXAMIDE INHIBITORS OF HIV INTEGRASE | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2011-02-10 | — | — | US | disclosed |
| US-7820660-B2 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2010-10-26 | — | — | US | disclosed |
| US-20080275004-A1 | N-Substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | MSD ITALIA S.R.L. (IT) | 2008-11-06 | — | — | US | disclosed |
| US-7435734-B2 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2008-10-14 | — | — | US | disclosed |
| US-20070123524-A1 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | MSD ITALIA S.R.L. (IT) | 2007-05-31 | — | — | US | disclosed |
| US-7217713-B2 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | ISTITUTO DI RICHERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2007-05-15 | — | — | US | disclosed |
| US-7169780-B2 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | ISTITUTE DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2007-01-30 | — | — | US | disclosed |
| US-20060258860-A1 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | MSD ITALIA S.R.L. (IT) | 2006-11-16 | — | — | US | disclosed |
| EP-1441735-B1 | N-SUBSTITUTED HYDROXYPYRIMIDINONE CARBOXAMIDE INHIBITORS OF HIV INTEGRASE | ANGELETTI P IST RICHERCHE BIO (IT) | 2006-02-22 | — | — | EP | disclosed |
| US-20050025774-A1 | N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase | MSD ITALIA S.R.L. (IT) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275004-A1 | N-Substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | IMPDH1, REV1, CCNI | CA12 4699/4885CA1 4353/4885CA2 2752/4885 |
| US-20110034449-A1 | N-SUBSTITUTED HYDROXYPYRIMIDINONE CARBOXAMIDE INHIBITORS OF HIV INTEGRASE | IMPDH1, REV1, CCNI | CA12 4699/4885CA1 4353/4885CA2 2752/4885 |
| US-20060258860-A1 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | IMPDH1, ASS1, REV1 | CA12 4749/4885CA1 4397/4885CA2 2647/4885 |
| US-20070123524-A1 | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase | IMPDH1, REV1, CCNI | CA12 4699/4885CA1 4353/4885CA2 2752/4885 |
| US-20050025774-A1 | N-substituted hydroxypyrimidinone carboxamide inhibitors of hiv integrase | IMPDH1, CCNI, REV1 | CA12 4722/4885CA1 4366/4885CA2 2890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.